Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DTG, I don't interpret Durrant's comments as you do. I think the key is in what was not said. It does not consider the reasons why the bankruptcy court judge is discharging the case as a CH11. I'm glad that you recognize the potential of a looming recall of the loaned shares. But the magnitude of that impact, when it comes, will be far from some pittance for the poor Humanigen shareholders.
I'm not discounting the reasonableness of anyone who comes to that deduction. In fact, I recognize that my own estimation of the value of lenz in treating covid needs more than just an appreciation of the safety and efficacy of the product. The value I attach to lenz for covid requires a degree of necessity that that value comes to light. Now, that necessity is becoming exposed, by the deadly health effects of the mRNA vaccines. The medical community needs to see that lenz has a role in helping to prevent covid pneumonia infection, without contributing to excess deaths overall. They need to see that lenz is the best therapeutic capable of safely curing the infection, and that lenz can prevent future reoccurrences of covid.
I think the stage is set to showcase lenzilumab's role in fighting covid, both as a prophylaxis, and as a therapeutic. And I think Novavax may become the partner we need to establish control of the worldwide covid market. I think those steps must be taken, for the protection of the populace. And I believe those steps are being taken.
I still wish you are correct here and that we get something to cause a recall of those loaned shares. So I haven't given up here just yet, even though it doesn't look good for us at this point in time.
I'm sorry Jay, but this was posted by Cameron himself:
Following an amazing eight-year, hugely intense journey at Humanigen, we recently closed the acquisition of the Humanigen assets and placing them in Taran, a Delaware C-corporation, with UK and Australian wholly-owned subsidiaries.
Taran is focused on helping bring life-saving medicines to patients, including lenzilumab ("LENZ") and ifabtotuzumab ("IFAB") in various leukemias, Graft vs. Host Disease and cancer, with possibilities in multiple other areas of high unmet medical need.
Taran is the Welsh word for "thunder". My wife bred a beautiful male Welsh cob foal, who was born during a thunderstorm and named him Taran.
The choice of Taran for the new company name honors her memory, as well as the beauty, pride and strength of the Welsh people and language and the physical and mythical power of thunder as an unstoppable force.
It's been a year since Humanigen filed a 10-Q, which indicated a cash balance of about $3.1M.
pg 4
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm
The bankruptcy filing claimed a cash balance of only about $500K.
https://www.reuters.com/business/healthcare-pharmaceuticals/covid-19-treatment-developer-humanigen-files-chapter-11-bankruptcy-2024-01-04/#:~:text=Jan%204%20(Reuters)%20%2D%20Drug,for%20its%20COVID%2D19%20treatment.
And we know the bankruptcy judge had approved of Taran providing $1M in financing, ahead of the closing of the bankruptcy, when they paid an additional $1M.
So we could have about $4M of additional lenz either produced, or scheduled to be produced. Starting a revenue stream is a required objective for Humanigen/Taran, and with Durrant investing millions into the operation at this point, I don't see why I should be worried, if he isn't.
The frenemies who, along with the FDA, kept us out of the market, are themselves now financially threatened. People are waking up to the harm inflicted by the mRNA vaccines. That is resulting in substantial revenue declines for Pfizer and Moderna, and steep cuts in FDA funding operations from Big Pharma, including licensing fees required of Big Pharma to the FDA.
If we get Novavax to use lenz under the approved IND authorization, to enhance the efficacy their vaccine with our patented formulation, we will own the covid market. Investors will be clamoring to buy shares, and Humanigen owns ~90% of the Outstanding Shares. But prospective buyers will have to compete with brokerages who will be faced with a recall of the loaned shares.
And that is just looking at the covid scenario, which seems more likely than ever, and much larger than ever. We also know that CMML treatment approval looks likely in Australia.
Taran can do nothing to meet the demand for shares.
Well, you are correct there are a ton of doses that were in production, but they are a year or two old and one would wonder when they will expire and are worthless. So again, Lenz IP no longer exists with HGENQ. HGENQ is a shell company. It has zero IP and does not manufacture. So really HGENQ has nothing unless something major happens and that is total speculation
I don't see how anyone could say that Humanigen has nothing to do with lenz. How much of the product in the pipeline does Taran own?
"I definitely could have blended right in with those guys."
In fact, believe it or not, I love to sing in choirs, and some of 'John's Boys' heard some of my country covers, and wanted me to join the group. I declined, because they wanted to re-imagine the choir, and become the ChippenWales.
Well, I did say, believe it, or not.
Yes, lens is out of our hands now as we just own an empty shell at this point. Hopefully a nice reverse merger comes in here down the road.
You are welcome for the reminder. Keep in mind, right now HGENQ does not own Lenz and has nothing to do with Lenz. Maybe you should take your Lenz thoughts and comments to the Taran message board, because they own the drug and keep this board about HGENQ
I initiated this thread by focusing on lenzilumab's strong binding affinity and slow off-rate. I think Ivermectin can be a useful therapeutic against covid (it seems to actually bind the covid spike protein), instead of binding GM-CSF. But it seems that as soon as Ivermectin is ceased, all the symptoms patients were suffering come roaring back. It's just an issue I would like to know more about, if regulators continue to keep lenzilumab on the shelf.
Additionally, there is an issue regarding significantly reduced energy levels. That affects me, and I've got a couple acres of land I've got to maintain this spring. I thought it was my being lazy, progressing to just becoming lazier. But this is now ridiculous, and even somewhat debilitating. That's another reason I want to look into this subject. I had already practically self-diagnosed myself as having Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptoms can include problems thinking and concentrating, which I try to alleviate with staying engaged here (just don't make me read another 10-Q, or anything else from a bankruptcy court filing), and practically becoming house-bound (but I've always been a homebody).
Anyway, thank you for letting me know that Humanigen doesn't own the lenz IP. I don't anticipate that will adversely impact the safety and efficacy of lenz. Nor do I think it will result in one less short share being recalled. When that happens, I might even get to enjoy a curative dose of adrenaline!
It doesn't matter how they benefit from owning the IP, they own it and we don't
Both Sanofi and Novavax have been tending to details regarding Beneficial Ownership Statements.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&owner=include&count=40&hidefilings=0
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001000694&owner=exclude
How does it benefit Taran to own the IP to a drug that has a strong binding affinity (25 pM) and a slow off-rate?
And HGENQ no longer owns the IP
For further study:
"Lenzilumab is a novel Humaneered® anti-human GM-CSF monoclonal antibody that binds directly to the GM-CSF and blocks further signalling through its receptor. It also showed strong binding affinity (25 pM) and a slow off-rate
https://link.springer.com/article/10.1007/s10787-021-00903-x
Ivermectin, and it's binding of the spike protein
In my initial reply to your post, I failed to acknowledge the first clause in your question. The answer, despite my earlier language in an unrelated post, is that, yes, all is well with me.
However, someone I care about is having some health issues, and I wanted her to see the videos in a couple of my posts. She had told me that she has had some boosters, following a Pfizer vaccine. I have never had a post rejected on this site, AND blocked on X. But, there's a first time for everything. So I had to email the videos to her, and hope that she can open the videos from her email, or that she finds those videos in other of my postings here.
You also expressed some question about Humanigen's right to use lenz. And I see others here also concerned about our future.
For years, I have talked about the "script" written in our company's history. In 2015, as now, the company was forced into a CH11 bankruptcy, just as we were again forced to do. And too many shareholders are failing to continue looking to our past, to project our future. This wasn't The End of the company in 2015, and it isn't The End of the company now, either.
Shareholders need to realize that Humanigen remains on track toward accomplishing their goals. If there has been a change, I think we may see management rely more on foreign regulatory approval. Certainly, we are seeing the British parliament address issues such as excess deaths from mRNA vaccines. This has got to force the MHRA to abandon the status quo, and to consider granting approval of lenz to treat covid.
Other treatments could even capitalize on plant-based alternatives to controlling cytokine release syndrome.
https://www.nasdaq.com/press-release/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives-2021-12-06
I think we may be in an ETF with them (but don't ask me to explain that). All I could do was to buy a small number shares in the company.
Finally, to me, there was an unknown distinction between SAR-S CoV-2 coronavirus in nucleocapsid proteins, caused by the virus, versus covid spike proteins caused by the mRNA vaccines. I really hope that a study has been done focused on the reduction of nucleocapsid covid proteins after administering lenz.
The only source I have for this observation is Bret Weinstein. I've hear him comment about the Chinese immigrants in various interviews, and you can hear what he tells Joe Rogan from the 4:05 minute mark.
MP Andrew Bridgen addresses British Parliament on the issue of excess deaths due to mRNA vaccines.
At the 7:30 minute mark, he quotes an expert opinion that the cause of these excess deaths has to be the experimental mRNA vaccines.
Or more than likely the various nationalities segregate themselves out of safety and protection? Most likely don’t speak Spanish and limited English being translated between non native English speakers sound confusing as hell haha!
I had a friend who went through the Darien gap to film a documentary, he hasn’t been the same since, mentally and physically. It’s a life changing dangerous trek…I would isolate myself to those I know or can relate too also if I was in that position.
This isn’t meant to be an argumentative post on the border issue from my end.
A lot of our presentations are no longer available, which is where I thought this was communicated. I'll keep looking. I've seen so many slides recently with covid spike proteins, and SARs-CoV2 nucleocapsid proteins, throughout the body, I may have mis-learned how those proteins get there.
It's very alarming that the Chinese illegal immigrants, who cross the border just as other foreign nationals are crossing the border, apparently segregate themselves while making the trek here, and seem to have their own camp sites on the trail, such as they have in San Vicente, in the Darien Gap. Non-Chinese are prohibited from even entering that camp site, and the Chinese do not communicate with the others. I haven't mentioned that earlier, because I only have a single source for that information. But my point is that I think this represents a serious threat of biological attack to our country. Yes, we have only found one (combined from two) illegal biotech labs being operated by Chinese nationals on our soil, and we only have two Chinese balloons (which can be equipped with biological dispersion capability) that have been observed in our airspace. But we also have illegal immigrants from the Middle East entering our country. The point is, that we cannot tolerate the lack of a true covid vaccine, or not having a safe and effective covid therapeutic that will also prevent rebound infections.
Covid will never be over. But lenz can prevent covid pneumonia infections in the future.
Come on, covid is over... I agree with the others that the asset is gone, we're left with an empty shell.
We have to assume that Humanigen has a license to use lenz, since Taran bought the IP...or, we just need to see the merger or business combination between Taran and Humanigen. I think that Humanigen has every intention to use lenz for covid, or Durrant would have simply bought out Humanigen.
HI JAY, HOPE ALL IS WELL ... SIMLE QUESTION: DOES HGEN STILL OWN OR HAVE RIGHTS TO LENZ??? _____ IF NOT, WHAT THEN? ... CORPORATE SHELLS CAN RE-EVOLVE INTO PROSPERING ENTITIES BUT MUST HAVE THE BONES TO BUILD UPON, THANX ....
Yes, I think that WAS the Big Pharma/Government objective, to keep us dependent on them.
But, too much evidence is surfacing that the mRNA vaccines (maybe even the adenovirus ones), are causing excess deaths. And I hope that Durrant is going to capitalize on the British Parliament's intent to put a stop to that, and the MHRA may finally approve lenz for covid.
Yes and no, ben. Durrant has gotten FDA approval of many drugs throughout his career, including several that proved to be blockbusters. So I think that demonstrates that he is actually an expert at knowing "what it takes to get a drug approved."
But that also means that regulators can't bullshit him. Yet, that is what they are trying to do. So Durrant knows what he has to do now.
The thing I like about Novavax is that they got regulatory approval from countries all around the world, before trying to get FDA approval in the US. The CEO they had was smart enough to do that, but fell short of managing operations afterwards. So they have a new CEO, and he seems better at managing operations. And I hope they end up partnering with Humanigen, and use lenz as a vaccine enhancement.
But we need lenz approved by a regulator, and I think the UK will finally be the regulator that approves lenz? Why? Because they have to.
My focus lately has been been on the UK's response to reality. I've been showing videos that graphically demonstrate that reality (for my reference, I'm talking about post numbers 42034 and 42035). Still, there is enough video evidence that I've been permitted to show that Humanigen's/Taran's lenz should be used in place of the mRNA vaccines. The proof is incontrovertible.
Not only are doctors/embalmers seeing novel presentations of the deadly blood clots they are finding post-mortem, actuaries and researchers are substantiating the physical evidence with statistical evidence. They are demonstrating multiple findings, such as significant excess deaths, in those patients who had mRNA vaccines.
In Durrant's post (which I still can't find) about Taran's objectives going forward, he didn't specifically mention covid. I hope, however, that's because Humanigen may continue that effort after they recall their loaned shares, and therefore have the funds to proceed.
Big Pharma did not want anything that would actually treat Covid to come out. It was always about the Vaccine and will always be about the Vaccines.
Let's just get it back to $18 dollars again and there would be no complaints from me! LOL :))))
Management gets the blame because they don't understand what it takes to get a drug approved. They couldn't get it over the finish line. That is their job. That is what they get paid for, drug approval. A coach can have the best team in the world but if they don't win a championship, the coach and team is subpar. And that is this management, subpar
Hey Jay, I must have missed this somewhere in the last couple of years. Could you please link or paste where this comes from?
This is what management did.
"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009; table 2a,
figure 2B). Separation of the survival curves appeared earlier
than in the overall population and followed a similar pattern
as the overall population thereafter (figure 2B). The number
needed to treat (NNT) was nine for this group compared with
17 for the overall population (table 2A). SWOV, in response to
lenzilumab treatment, was similar to placebo in participants with
CRP ≥150 mg/L at baseline (table 2A and figure 2C). The NNT
for this group was 37 (table 2A)"
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
How can you look at those results, and NOT blame the FDA for withholding our EUA? That shows stellar performance of lenzilumab, captured brilliantly by the LIVE-AIR trial investigators.
Nice Braveheart speech. Management should have never gone it alone. They were greedy and hurt shareholders. They failed in their fiduciary responsibility. They must be horrible doctors if this is how they view fulfilling oaths
The disgrace belongs to people like us, for failing to demand accountability from our government, who focuses on "government of the people," and never has to worry about that governance being exercised "by the people, and for the people." All discretionary authority should be rescinded from government agencies.
But, in our case, management didn't intend to treat covid, when they took over the company, which was almost 3 years before covid arrived. When the disease hit, management had no choice but to put lenzilumab into the fight. They were right to do so. They are doctors bound by an Hippocratic Oath.
"I shall work with my profession to improve the quality of medical care and to improve the public health, but I shall not let any lesser public or professional consideration interfere with my primary commitment to provide the best and most appropriate care available to each of my patients."
Lenzilumab is the only therapeutic that binds GM-CSF and prevents the virus from infecting the intended receptor cells. And as importantly, it imbues an appropriate immune response to prevent future infections. Even now, our MOA offers the most effective solution to fight covid.
Where would the world be right now, if the FDA had approved our EUA application in May of 2021?
https://ir.humanigen.com/English/news/news-details/2021/-Humanigen-Submits-Application-to-FDA-for-Emergency-Use-Authorization-for-Lenzilumab-in-COVID-19/default.aspx
Instead, where are we now? We have covid deaths ranging from 7M - 20M, by some estimates. AND, we have no safe and effective TRUE vaccine, nor do we have a safe and effective therapeutic, both of which we would likely have, if lenz was approved. This is no time to still our voices, and surrender. Preventable deaths are occurring every single day.
And this is why Humanigen's management is a disgrace. They should have never tried to challenge the system. They were too pigheaded. I am not saying I agree with the big pharma game, but big pharma controls the rules and Humanigen screwed all of the shareholders by trying to buck the system
Big Pharma provides 65% of FDA funding, and 86% of MHRA funding.
This is according to Dr. Aseem Malhotra, as he claimed in an interview with Tucker. If this is true, how can a small biotech like Humanigen, even with a mega-blockbuster drug, which lenzilumab is, ever get Regulatory approval?
See minute mark 23:50 of the video linked below.
Andrew Bridgen, MP, requests meeting with Scotland Yard, "...regarding, "Very serious criminal offences to name but a few, Misconduct in Public Office, Misfeasence in Public Office, Gross Negligent Manslaughter, Corporate Manslaughter, Fraud, Murder, Manslaughter and Grievous Bodily Harm,.." and more, regarding the Coronavirus pandemic and vaccination program.
https://www.linkedin.com/posts/andrewpearce_andrew-bridgen-mp-abridgen-on-x-activity-7171096018267131904-dnT4
This is of significant relevance to Humanigen, as an appropriate Regulatory response would include the authorization and approval of lenzilumab to treat covid prophylactically as a vaccine adjuvant, and therapeutically.
The safety and efficacy of lenz has resulted in meeting the primary endpoint in the company-sponsored LIIVE-AIR trial, and the results have been peer-reviewed by both Lancet and Thorax.
https://www.humanigen.com/
Novel presentations of blood clots, including long white fibrous strands of blood clots, are being discovered in the bodies of patients who had multiple mRNA vaccinations. They have also resulted in covid spike proteins located in organs such as the brain and heart. as shown in the following videos.
LOL :) That was pretty good, and you almost made me choke on my coffee. LOL You are right in that we at least have the hat! :))
I think the only rabbit out of the hat trick was pulled by Durrant taking everything that had value in HGEN for $2milly and leaving shareholders with an empty hat haha!
At least we still have the hat, maybe someone will put something in it worth a dime or two a share in future….
Edit "...6.9M American,,," should have read 6.9M worldwide deaths. Americans accounted for 1.123M of the total deaths as of one year ago.
https://coronavirus.jhu.edu/map.html
Unfortunately, this is what I am seeing too. I am an eternal optimist, but I just don't see how this is good for HGEN shareholders???
Like Yourself I am hoping someone can buy the shell and get us relisted again and that maybe we can get a nice run to .05 to .10 cents if we're lucky?
At least we are chapter11 and the stock will survive. The shell should be worth something in the future here especially being debt free after the bankruptcy is discharged.
I would absolutely love to see a rabbit pulled out of the hat here, and Jay somehow be right! I would love that more than anything else, but it looks like Taran got the Gold and while we got the Shaft. LOL
Dr Durant: Following an amazing eight-year, hugely intense journey at Humanigen, we recently closed the acquisition of the Humanigen assets and placing them in Taran, a Delaware C-corporation, with UK and Australian wholly-owned subsidiaries.
Where have you been, OneDay? What I saw yesterday was hardly a sign of short covering.
"The short sale volume percent (not short interest) for stock ticker HGENQ is 99.74% on Mar 08, 2024. The short sale volume is 190,171. The total volume is 190,671."
http://shortvolumes.com/?t=hgenq
Maybe some brokerage was caught charging a client short interest, without having secured a locate.
Thank you, JA3. I am of Irish, German, and Welsh descent, myself. I was glad to see a male choir from Wales perform on Britain's Got Talent last year. I thought BGT judge Amanda Holden was simply going to melt, just listening to them. I definitely could have blended right in with those guys, without buying a new wardrobe. I wonder if I had family in that group, LOL! I just felt right at home with them.
All the volume since delisting is the shorts covering ??
Taran got the assets, we have worthless stock that can barely be given away lol!
Maybe this will be a shell that gets pumped and dumped for a run with claims of getting into Artificial Intelligence or something.
It’s a post by Cameron:
Following an amazing eight-year, hugely intense journey at Humanigen, we recently closed the acquisition of the Humanigen assets and placing them in Taran, a Delaware C-corporation, with UK and Australian wholly-owned subsidiaries.
Taran is focused on helping bring life-saving medicines to patients, including lenzilumab ("LENZ") and ifabtotuzumab ("IFAB") in various leukemias, Graft vs. Host Disease and cancer, with possibilities in multiple other areas of high unmet medical need.
Taran is the Welsh word for "thunder". My wife bred a beautiful male Welsh cob foal, who was born during a thunderstorm and named him Taran.
The choice of Taran for the new company name honors her memory, as well as the beauty, pride and strength of the Welsh people and language and the physical and mythical power of thunder as an unstoppable force.
"Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license
By Eric SagonowskyFeb 24, 2023"
https://www.fiercepharma.com/pharma/moderna-pays-us-government-400m-catch-payment-under-new-covid-19-vaccine-license
Wut da problem is?
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43436
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |